Non-Hodgkin lymphoma treatment Market
Non-Hodgkin Lymphoma Treatment Market Size, Share & Trends Analysis Report by Therapy Class (Chemotherapy, Immunotherapy, Targeted Therapy, Cell Therapy, Others), by Disease Type (B-cell Lymphomas, T-cell Lymphomas), by End-Use Industry (Hospitals, Specialty Cancer Centers, Ambulatory Care Centers), and Forecast Period (2026–2035)
Industry Overview
Non-hodgkin lymphoma treatment market was valued at $7.9 billion in 2025 and is projected to reach $17.8 billion by 2035, registering a CAGR of 8.6% from 2026 to 2035. Market growth is primarily driven by the rising prevalence of hematologic cancers and the increasing adoption of advanced treatment modalities such as monoclonal antibodies, CAR-T cell therapies, and targeted small molecules. The ongoing shift from conventional chemotherapy to precision medicine is significantly enhancing treatment efficacy and patient outcomes, thereby accelerating revenue expansion. In addition, the growing demand for immunotherapies and biologics is supported by favorable regulatory approvals and expanding reimbursement frameworks across developed markets. Furthermore, the increasing penetration of biosimilars is improving treatment accessibility and affordability, particularly in emerging economies, contributing to broader market growth.
Recent developments highlight continued innovation and access expansion within the market. In April 2026, Novartis announced the expansion of its community health programs aimed at improving cancer care access across more than 30 countries by 2030, with a focus on early diagnosis, enhanced treatment availability, and stronger referral systems in underserved regions. Similarly, in December 2024, Gilead Sciences (Kite) reported positive outcomes for its CAR-T therapies, Yescarta and Tecartus, in patients with relapsed or refractory large B-cell lymphoma and mantle cell lymphoma at the ASH 2024 meeting. The findings, supported by real-world evidence and long-term clinical data, reinforced the effectiveness of CAR-T therapies in advanced cases. Collectively, these developments underscore strong pipeline progress and the increasing commercialization of next-generation lymphoma treatments.
Market Dynamic
Bispecific Antibodies Transform First-Line NHL Treatment Landscape
Monoclonal antibodies continue to dominate the Non-Hodgkin lymphoma treatment market, particularly in B-cell lymphomas, due to their strong clinical efficacy and widespread use in first-line therapy. CD20-targeting therapies have significantly improved patient survival and remain a cornerstone of hospital-based treatment protocols. The segment is further evolving with the emergence of next-generation bispecific antibodies that enhance immune response against cancer cells. In December 2025, Roche received U.S. FDA approval for the subcutaneous formulation of Lunsumio (mosunetuzumab) for relapsed or refractory follicular lymphoma. The therapy demonstrated high response rates while reducing administration time from hours to approximately one minute, significantly improving patient convenience. This advancement supports the shift toward outpatient care settings and reinforces the growing role of innovative monoclonal antibody therapies in NHL treatment.
CAR-T Breakthrough Redefining Survival in Relapsed Lymphoma
CAR-T therapy is transforming outcomes in relapsed/refractory Non-Hodgkin lymphoma by delivering strong responses where conventional treatments fail. These therapies are administered mainly in specialized centers due to their complexity and monitoring needs. Their ability to provide long-term remission is positioning CAR-T as a breakthrough in advanced lymphoma care. In December 2024, Gilead Sciences reported that its CAR-T therapy Yescarta showed durable responses and long-term survival benefits in NHL patients. The results were based on five-year follow-up data from the ZUMA-5 study presented at ASH 2024. Over half of the treated patients remained alive without needing additional therapy. These findings highlight the strong potential of CAR-T therapies in difficult-to-treat cases. The results further support the growing adoption of CAR-T in advanced lymphoma treatment.
Market Segmentation
- Based on therapy class, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, Cell Therapy, Others.
- Based on disease subtype, the market is segmented into B-cell lymphomas and T-cell lymphomas.
- Based on route of administration, the market is segmented into intravenous (IV), oral, and subcutaneous (SC).
- Based on end-user, the market is segmented into hospitals, specialty cancer centers, and ambulatory care centers.
Oral Therapies Transforming Lymphoma Care
Oral targeted therapies, especially BTK inhibitors, are rapidly gaining adoption in lymphoma treatment due to their convenience and ability to support long-term disease management. These therapies reduce hospital dependency and improve patient compliance compared to traditional IV treatments. In December 2025, clinical data presented at the showed that the oral BTK inhibitor pirtobrutinib significantly improved progression-free survival over standard chemoimmunotherapy. The study also demonstrated a strong safety profile with fewer adverse effects. These results highlight the growing clinical preference for oral therapies. The findings are expected to accelerate global adoption across hospitals and specialty cancer centers.
Hospitals Lead NHL Treatment as Global Cancer Burden Intensifies
Hospitals dominate Non-Hodgkin lymphoma (NHL) treatment delivery due to their advanced infrastructure, specialized oncology units, and ability to administer complex therapies such as CAR-T, monoclonal antibodies, and chemotherapy. The need for continuous monitoring and multidisciplinary care further strengthens hospital dependence in this market. In April 2026, the World Health Organization reported that cancer remains a leading global health burden, highlighting the critical importance of early diagnosis and access to advanced treatments. The organization emphasized that effective cancer care requires timely intervention and well-equipped healthcare systems. It also noted that access to specialized treatment infrastructure remains uneven globally, increasing pressure on hospital systems. This rising burden is significantly driving demand for advanced therapies, including those used in NHL treatment.
Regional Outlook
The global non-hodgkin lymphoma treatment market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America is the leading Region in the market
North America leads the Non-Hodgkin lymphoma treatment market due to its advanced oncology infrastructure, high healthcare expenditure, and rapid adoption of innovative therapies such as CAR-T and biologics. The region benefits from strong clinical capabilities and the presence of major pharmaceutical manufacturers, enabling early access to cutting-edge treatments. In April 2025, Novartis announced a $23 billion investment over five years to expand its U.S.-based manufacturing and R&D footprint, including facilities for biologics and advanced therapies. This expansion focuses on establishing end-to-end production capabilities within the U.S., particularly for high-value oncology treatments. The initiative is expected to strengthen the supply chain for CAR-T therapies used in Non-Hodgkin lymphoma. It also enhances regional treatment accessibility while supporting the growing demand for advanced cancer therapies across North America.
Market Players Outlook
The major companies operating in the global non-hodgkin lymphoma treatment market include Roche, Novartis, Gilead Sciences, Bristol Myers Squibb, and AbbVie, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In April 2025, Pfizer announced advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, showcasing over 60 research abstracts across multiple tumor types, including hematologic cancers. The company highlighted progress in antibody-drug conjugates and combination therapies, which are increasingly relevant in lymphoma treatment. These developments support ongoing innovation in targeted and immunotherapy approaches within the non-Hodgkin lymphoma treatment market.
- In May 2024, Takeda Pharmaceutical Company announced that it will present clinical and real-world data from its oncology pipeline at the ASCO 2024 Annual Meeting, including research in lymphoma and other hematologic cancers. The presentations highlight advancements in treatment approaches aimed at improving patient outcomes and optimizing care in lymphoma therapies. This development reflects Takeda’s continued focus on expanding its oncology portfolio, particularly in hematologic malignancies such as lymphoma, supporting innovation in the NHL treatment market.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global non-hodgkin lymphoma treatment market.
- Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Non-Hodgkin Lymphoma Treatment Market Sales Analysis – Therapy Class | Disease Type | End User ($ Million)
- Non-Hodgkin Lymphoma Treatment Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach Analytics
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Non-Hodgkin Lymphoma Treatment Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers of Non-Hodgkin Lymphoma Treatment Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Non-Hodgkin Lymphoma Treatment Market: Impact Analysis
- Market Opportunities
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Non-Hodgkin Lymphoma Treatment Market Revenue and Share by Manufacturers
- Non-Hodgkin Lymphoma Treatment Type Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Roche
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AbbVie
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Non-Hodgkin Lymphoma Treatment Market Sales Analysis Therapy Class ($ Million)
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Cell Therapy
- Others
- Non-Hodgkin Lymphoma Treatment Market Sales Analysis Disease Type ($ Million)
- B-cell Lymphomas
- T-cell Lymphomas
- Non-Hodgkin Lymphoma Treatment Market Sales Analysis End User ($ Million)
- Hospitals
- Specialty Cancer Centers
- Ambulatory Care Centers
- Regional Analysis
- North American Non-Hodgkin Lymphoma Treatment Market Sales Analysis – Therapy Class | Disease Type | End User| Country ($ Million)
- United States
- Canada
- North American Non-Hodgkin Lymphoma Treatment Market Sales Analysis – Therapy Class | Disease Type | End User| Country ($ Million)
- European Non-Hodgkin Lymphoma Treatment Market Sales Analysis – Therapy Class | Disease Type | End User| Country ($ Million)
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Sales Analysis – Therapy Class | Disease Type | End User| Country ($ Million)
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the Non-Hodgkin Lymphoma Treatment Market Sales Analysis – Therapy Class | Disease Type | End User| Country ($ Million)
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BeiGene
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol Myers Squibb
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Genmab
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Gilead Sciences
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Incyte
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jazz Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Karyopharm Therapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- MorphoSys
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Regeneron Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Roche
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Seagen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Servier
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Spectrum Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie
1. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Therapy Class, 2025-2035 ($ Million)
2. Global Chemotherapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
3. Global Immunotherapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
4. Global Targeted Therapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
5. Global Cell Therapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
6. Global Others Therapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
7. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Disease Type, 2025-2035 ($ Million)
8. Global B-cell Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
9. Global T-cell Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
10. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis By End User, 2025-2035 ($ Million)
11. Global Non-Hodgkin Lymphoma Treatment For Hospitals Market Research and Analysis By Region, 2025-2035 ($ Million)
12. Global Non-Hodgkin Lymphoma Treatment For Specialty Cancer Centers Market Research and Analysis By Region, 2025-2035 ($ Million)
13. Global Non-Hodgkin Lymphoma Treatment For Ambulatory Care Centers Market Research and Analysis By Region, 2025-2035 ($ Million)
14. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
15. North American Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
16. North American Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Therapy Class, 2025-2035 ($ Million)
17. North American Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Disease Type, 2025-2035 ($ Million)
18. North American Non-Hodgkin Lymphoma Treatment Market Research and Analysis By End User, 2025-2035 ($ Million)
19. European Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
20. European Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Therapy Class, 2025-2035 ($ Million)
21. European Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Disease Type, 2025-2035 ($ Million)
22. European Non-Hodgkin Lymphoma Treatment Market Research and Analysis By End User, 2025-2035 ($ Million)
23. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
24. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Therapy Class, 2025-2035 ($ Million)
25. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Disease Type, 2025-2035 ($ Million)
26. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Research and Analysis By End User, 2025-2035 ($ Million)
27. Rest of the World Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
28. Rest of the World Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Therapy Class, 2025-2035 ($ Million)
29. Rest of the World Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Disease Type, 2025-2035 ($ Million)
30. Rest of the World Non-Hodgkin Lymphoma Treatment Market Research and Analysis By End User, 2025-2035 ($ Million)
1. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Therapy Class, 2025 Vs 2035 ($ Million)
2. Global Chemotherapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
3. Global Immunotherapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
4. Global Targeted Therapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
5. Global Cell Therapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
6. Global Others Therapy for Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
7. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Disease Type, 2025 Vs 2035 ($ Million)
8. Global B-cell Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
9. Global T-cell Non-Hodgkin Lymphoma Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
10. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis By End User, 2025 Vs 2035 ($ Million)
11. Global Non-Hodgkin Lymphoma Treatment For Hospitals Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
12. Global Non-Hodgkin Lymphoma Treatment For Specialty Cancer Centers Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
13. Global Non-Hodgkin Lymphoma Treatment For Ambulatory Care Centers Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
14. US Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
15. Canada Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
16. UK Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
17. France Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
18. Germany Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
19. Italy Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
20. Spain Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
21. Russia Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
22. Rest of Europe Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
23. India Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
24. China Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
25. Japan Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
26. South Korea Non-Hodgkin Lymphoma Treatment, 2025-2035 ($ Million)
27. Australia and New Zealand Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
28. ASEAN Economies NON-HODGKIN LYMPHOMA TREATMENT Market Size, 2025-2035 ($ Million)
29. Rest of Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
30. Latin America Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
31. Middle East and Africa Non-Hodgkin Lymphoma Treatment Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
